WallStreetZenWallStreetZen

NASDAQ: SRTS
Sensus Healthcare Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for SRTS

Based on 1 analyst offering 12 month price targets for Sensus Healthcare Inc.
Min Forecast
$16.00+29.35%
Avg Forecast
$16.00+29.35%
Max Forecast
$16.00+29.35%

Should I buy or sell SRTS stock?

Based on 1 analyst offering ratings for Sensus Healthcare Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SRTS stock forecasts and price targets.

SRTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 5%
96
BuyMaintains$16.00+29.35%2022-05-06

1 of 1

Forecast return on equity

Is SRTS forecast to generate an efficient return?
Company
34.92%
Industry
15.51%
Market
98.76%
SRTS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SRTS forecast to generate an efficient return on assets?
Company
27.91%
Industry
9.04%
SRTS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRTS earnings per share forecast

What is SRTS's earnings per share in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$0.77-49.01%
Avg 2 year Forecast
$0.95-37.09%
SRTS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

SRTS revenue forecast

What is SRTS's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$43.7M+6.78%
Avg 2 year Forecast
$49.6M+21.12%
SRTS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SRTS earnings growth forecast

How is SRTS forecast to perform vs Medical Devices companies and vs the US market?
Company
-49.01%
Industry
55.77%
Market
46.52%
SRTS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SRTS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SRTS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SRTS revenue growth forecast

How is SRTS forecast to perform vs Medical Devices companies and vs the US market?
Company
6.78%
Industry
1.54%
Market
12.8%
SRTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SRTS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SRTS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
SRTS$12.37$16.00+29.35%Buy
APEN$5.15$10.67+107.13%Strong Buy
VMD$5.62$9.00+60.14%Buy
SPNE$5.80$15.00+158.62%Strong Buy
ARAY$2.05$7.33+257.71%Strong Buy

Sensus Healthcare Stock Forecast FAQ

Is Sensus Healthcare Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SRTS) stock is to Buy SRTS stock.

Out of 1 analyst, 0 (0%) are recommending SRTS as a Strong Buy, 1 (100%) are recommending SRTS as a Buy, 0 (0%) are recommending SRTS as a Hold, 0 (0%) are recommending SRTS as a Sell, and 0 (0%) are recommending SRTS as a Strong Sell.

If you're new to stock investing, here's how to buy Sensus Healthcare stock.

What is SRTS's earnings growth forecast for 2022-2023?

(NASDAQ: SRTS) Sensus Healthcare's forecast annual earnings growth rate of -49.01% is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 55.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 46.52%.

Sensus Healthcare's earnings in 2022 is $25,099,000.On average, 2 Wall Street analysts forecast SRTS's earnings for 2022 to be $12,748,139, with the lowest SRTS earnings forecast at $10,926,977, and the highest SRTS earnings forecast at $14,403,742.

In 2023, SRTS is forecast to generate $15,728,224 in earnings, with the lowest earnings forecast at $10,761,416 and the highest earnings forecast at $20,695,031.

What is SRTS's revenue growth forecast for 2022-2023?

(NASDAQ: SRTS) Sensus Healthcare's forecast annual revenue growth rate of 6.78% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 1.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.8%.

Sensus Healthcare's revenue in 2022 is $40,968,000.On average, 2 Wall Street analysts forecast SRTS's revenue for 2022 to be $724,243,314, with the lowest SRTS revenue forecast at $700,650,978, and the highest SRTS revenue forecast at $747,835,649.

In 2023, SRTS is forecast to generate $821,509,961 in revenue, with the lowest revenue forecast at $762,404,951 and the highest revenue forecast at $880,614,970.

What is SRTS's forecast return on assets (ROA) for 2022-2023?

(NASDAQ: SRTS) forecast ROA is 27.91%, which is higher than the forecast US Medical Devices industry average of 9.04%.

What is SRTS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SRTS price target, the average SRTS price target is $16.00, with the highest SRTS stock price forecast at $16.00 and the lowest SRTS stock price forecast at $16.00.

The Wall Street analyst predicted that Sensus Healthcare's share price could reach $16.00 by May 6, 2023. The average Sensus Healthcare stock price prediction forecasts a potential upside of 29.35% from the current SRTS share price of $12.37.

What is SRTS's Earnings Per Share (EPS) forecast for 2022-2023?

(NASDAQ: SRTS) Sensus Healthcare's current Earnings Per Share (EPS) is $1.51. On average, analysts forecast that SRTS's EPS will be $0.77 for 2022, with the lowest EPS forecast at $0.66, and the highest EPS forecast at $0.87. In 2023, SRTS's EPS is forecast to hit $0.95 (min: $0.65, max: $1.25).

What is SRTS's forecast return on equity (ROE) for 2022-2023?

(NASDAQ: SRTS) forecast ROE is 34.92%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.